Oligonucleotides for long QT syndrome

Case ID:
2044
Web Published:
1/29/2015
Description:

Summary

The current technology consists for compositions under development for the treatment of cardiovascular arrhythmias, specifically Long-QT Syndrome.

Technology Overview

KCNH2, also known as ether-a-go-go related gene 1 (hERG1) encodes the Kv11.1 channel that conducts the rapidly activating delayed rectifier K+ current in the heart. These channels are essential for cardiac action potential repolarization. Mutations in KCNH2 cause long QT syndrome type 2 (LQT2), a disease associated with prolonged cardiac action potential duration and prolonged QT intervals on ECG, which can lead to ventricular arrhythmia and sudden death.  The current morpholino oligonucleotides upregulate the Kv11.1 subunit of the hERG gene to treat long-QT syndrome caused by mutations.

Publication

Gong Q, et al., “Upregulation of functional Kv11.1 isoform expression by inhibition of intronic polyadenylation with antisense morpholino oligonucleotides.” J Mol Cell Cardiol. 2014 Nov;76:26-32. Link

Licensing Opportunity

This technology is available for licensing.

Patent Information:
Category(s):
Therapeutics
For Information, Contact:
Lisa Lukaesko
Technology Development Manager
Oregon Health & Science University
lukaesko@ohsu.edu
Inventors:
Zhengfeng Zhou
Qiuming Gong
Matthew Stump
Keywords:
Therapeutics
Therapeutics - General
Therapeutics - Other
© 2023. All Rights Reserved. Powered by Inteum